- In February 2025, CN Bio introduced the PhysioMimix® DILI assay kit: Human 24, a preclinical toxicology testing tool utilizing a human-derived liver micro-physiological system. This innovation enhances drug safety assessments by enabling simultaneous evaluation of multiple drug candidates, thereby improving efficiency in early-stage drug development.
- In September 2024, Eurofins Scientific acquired Infinity Laboratories, Inc., based in Castle Rock, Colorado. This strategic acquisition expanded Eurofins' biopharmaceutical and medical device network in the United States, strengthening its capabilities in toxicology testing and services across North America.
- In October 2023, Thermo Fisher Scientific launched the Thermo Scientific™ Meridian™ EX System, an electron-beam-based failure analysis solution designed for precise fault localization on advanced semiconductor logic technologies. This advancement contributes to the enhancement of toxicology testing methodologies by improving the accuracy and reliability of analytical processes.
- In December 2023, Merck introduced AIDDISON™, an innovative AI-driven drug discovery platform that integrates generative AI and machine learning. By evaluating over 60 billion compounds, it identifies drug candidates with desired properties like low toxicity and stability, significantly enhancing drug development efficiency and safety assessments.
- In April 2023, Roquette, a provider of pharmaceutical and nutraceutical excipients, opened a new $25 million pharmaceutical innovation center near Philadelphia. This facility serves as an advanced training and collaboration hub for pharmaceutical and nutraceutical manufacturers, focusing on optimizing patient experience with next-generation oral dosage forms and enhancing toxicology testing capabilities.
